摘要
Fms样酪氨酸激酶(FLT3)属于Ⅲ型受体酪氨酸蛋白激酶家族,其异常表达见于大部分急性髓性白血病(AML)病人,包括野生型受体与配体的协同表达,内部串连复制及活化环突变,表达持续性磷酸化活化的FLT3,对预后的判断具有重要意义。FLT3抑制剂主要有5类及热休克蛋白90抑制剂,实验室研究与初步的临床试验显示出其对AML的治疗价值。
Fms-like receptor tyrosine kinase-3 （FLT3） is a member of the class Ⅲ receptor tyrosine kinase family. Coexpression of wild-type receptor with its ligand, internal tandem duplications （ITD） and activation loop mutations lead to the consistent expression of phosphorylation-activited FLT3. These aberrant expressions of FLT3 have been detected in most acute myelogenous leukemia （AML） providing a prognostic significance. FLT3 inhibitors mainly include 5 varieties and heat shock protein 90 （ HSP90 ） inhibitor as well. These agents have shown promising effect on the therapy of AML in experiments and early clinical trials.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2005年第10期812-817,共6页
Chinese Journal of New Drugs and Clinical Remedies
关键词
白血病
粒细胞
急性
点突变
蛋白质
酪氨酸激酶
leukemia, myelocytic, acute
point mutation
protein-tyrosine kinase
